JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Kodu・Aktsiate loetelu・Pacira Pharmaceuticals Inc-DE

Pacira Pharmaceuticals Inc-DE

Suletud

SektorTervishoid

24.51 -3.16

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

24.2

Max

24.51

Põhinäitajad
By Trading Economics
Sissetulek	-3.8M 1.6M
Müük	17M 197M
P/E Sektori keskmine	155.625 60.328
Kasumimarginaal	0.832
Töötajad	825
EBITDA	-9.8M 25M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+12.2% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. apr 2026

Turustatistika
By TradingEconomics
Turukapital	77M 1.1B
Eelmine avamishind	27.67
Eelmine sulgemishind	24.51

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

24.83 / 26.38 Toetus ja vastupanu

Pacira Pharmaceuticals Inc-DE Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2026, 19:19 UTC

Omandamised, ülevõtmised, äriostud

Intertek Group Rejects EQT's Revised Offer

24. apr 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Scoring the Cook Era -- Barrons.com

24. apr 2026, 20:51 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

24. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 20:09 UTC

Tulu

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24. apr 2026, 19:48 UTC

Market Talk

Uudisväärsed sündmused

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24. apr 2026, 19:25 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 19:25 UTC

Omandamised, ülevõtmised, äriostud

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24. apr 2026, 19:22 UTC

Tulu

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24. apr 2026, 19:06 UTC

Tulu

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24. apr 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24. apr 2026, 18:30 UTC

Omandamised, ülevõtmised, äriostud

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24. apr 2026, 18:28 UTC

Omandamised, ülevõtmised, äriostud

Intertek Rejects Revised EQT Offer

24. apr 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24. apr 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24. apr 2026, 17:42 UTC

Tulu

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24. apr 2026, 17:28 UTC

Tulu

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24. apr 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24. apr 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24. apr 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24. apr 2026, 17:09 UTC

Market Talk

Tulu

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24. apr 2026, 17:09 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 17:06 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24. apr 2026, 16:51 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24. apr 2026, 16:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

24. apr 2026, 16:20 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

24. apr 2026, 16:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

24. apr 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Pacira Pharmaceuticals Inc-DE Prognoos

Hinnasiht

By TipRanks

12.2% tõus

12 kuu keskmine prognoos

Keskmine 27.5 USD 12.2%

Kõrge 38 USD

Madal 22 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Pacira Pharmaceuticals Inc-DE 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Pacira Pharmaceuticals Inc-DE aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

24.83 / 26.38Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

Bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.